{
    "nctId": "NCT02336984",
    "briefTitle": "A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS",
    "officialTitle": "A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Occurrence of Related Adverse Events (AEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women \\>= 18 years.\n* Ductal carcinoma in situ (DCIS) that express HER-2 3+ on 10% of the DCIS that have not had definitive surgery are diagnosed by core biopsy or NL surgical biopsy with positive margins.\n* Patients that are ER+ will take anti-estrogen therapy for treatment of their DCIS during vaccinations.\n* Women of childbearing age with a negative pregnancy test documented prior to enrollment.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1.\n* Women of childbearing potential must agree to use a medically acceptable form of birth control during their participation in the study.\n* Have voluntarily signed a written Informed Consent in accordance with institutional policies after its contents have been fully explained to them.\n\nExclusion Criteria\n\n* Pregnant or lactating.\n* Positive for HIV or hepatitis C at baseline by self-report.\n* Potential participants with coagulopathies, including thrombocytopenia with platelet count \\<75,000, INR\\> 1.5 and partial thromboplastin time \\> 50 sec\n* Major cardiac illness MUGA or ECHO \\<50% EF.\n* Pre-existing medical illnesses or medications which might interfere with the study as determined by Principal Investigator (PI).",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}